Nanomedicine Drug Delivery Market Report 2026

The nanomedicine drug delivery market size has grown rapidly in recent years. It will grow from $123.37 billion in 2025 to $142.7 billion in 2026 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to advancements in nanotechnology research, rising prevalence of chronic diseases, expansion of oncology drug development, increasing academic nanomedicine studies, early clinical success of nanoformulations.

The nanomedicine drug delivery market size is expected to see rapid growth in the next few years. It will grow to $252.69 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to increasing investments in precision therapeutics, rising demand for targeted drug delivery, expansion of nanomedicine clinical trials, growing integration of ai in formulation design, increasing regulatory clarity for nanodrugs. Major trends in the forecast period include increasing development of targeted nanocarrier systems, rising use of liposomal drug delivery platforms, growing adoption of stimuli-responsive nanomaterials, expansion of oncology-focused nanomedicine applications, enhanced focus on drug bioavailability improvement.

The increasing adoption of personalized medicine is expected to drive the growth of the nanomedicine drug delivery market in the coming years. Personalized medicine is a medical approach that tailors treatment and prevention strategies to the unique characteristics of each patient, such as their genetic profile or disease subtype. The adoption of personalized medicine is expanding as advances in genomics and molecular science enable treatments that are customized to an individual’s genetic makeup, improving efficacy and allowing precise, targeted care. Nanomedicine drug delivery facilitates personalized medicine by accurately delivering drugs to specific cells and adjusting dosages and formulations for each patient, enhancing treatment outcomes and minimizing side effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based international non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases in 2023, compared to six approvals in 2022. Consequently, the rising adoption of personalized medicine is supporting the expansion of the nanomedicine drug delivery market.

Major companies operating in the nanomedicine drug delivery market are concentrating on developing solutions such as AI-driven nano-delivery platforms to improve targeting accuracy and accelerate the creation of personalized therapies. AI-driven nano-delivery platforms are advanced systems that utilize artificial intelligence to design and optimize nanoparticles for precise drug delivery, improving therapeutic effectiveness while minimizing side effects and supporting personalized treatment. For example, in September 2025, METiS TechBio, a China-based biotechnology firm, introduced NanoForge, an AI-powered nano-delivery platform aimed at transforming the development and delivery of medicines. The system combines artificial intelligence with nanotechnology to refine lipid nanoparticle formulations and deliver drugs accurately to target tissues, enabling faster, safer, and more cost-efficient drug development. This innovation seeks to address major challenges in drug delivery for complex molecules such as mRNA, steering the field toward programmable and reconfigurable therapeutics.

In July 2024, ME Therapeutics Inc., a Canada-based preclinical-stage immuno-oncology company, formed a partnership with NanoVation Therapeutics Inc. to develop advanced messenger ribonucleic acid (mRNA) delivery systems targeting myeloid cells for cancer therapy. Through this collaboration, ME Therapeutics intends to utilize NanoVation’s proprietary long-circulating lipid nanoparticle (lcLNP) platform to improve the precision, efficacy, and in vivo targeting of mRNA therapeutics, thereby speeding up the development of novel treatments in the nanomedicine drug delivery field. NanoVation Therapeutics Inc. is a Canada-based biotechnology company focused on the design and development of lipid nanoparticle technologies for nucleic acid delivery.

Major companies operating in the nanomedicine drug delivery market are Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Evonik Industries AG, Ipsen Pharma S.A.S., Pacira BioSciences Inc., Camurus AB, Arcturus Therapeutics Holdings Inc., Nanobiotix S.A., Acuitas Therapeutics Inc., NanoViricides Inc., Taiwan Liposome Company Ltd., Aphios Corporation, Concept Medical Inc., DelSiTech Ltd., ANP Technologies Inc., ProMab Biotechnologies Inc., BlueWillow Biologics Inc., Nanoform Finland Plc.

North America was the largest region in the nanomedicine drug delivery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nanomedicine drug delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nanomedicine drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the nanomedicine drug delivery market by increasing costs of imported nanomaterials, specialized polymers, analytical instruments, and precision manufacturing equipment. Research institutes and pharmaceutical companies in North America and Europe are most affected due to reliance on high-value imported inputs, while Asia-Pacific faces increased costs for nanoformulation exports. These tariffs are raising development costs and slowing scale-up activities. However, they are also encouraging domestic material synthesis, localized manufacturing capabilities, and regional nanotechnology innovation ecosystems.

The nanomedicine drug delivery market research report is one of a series of new reports that provides nanomedicine drug delivery market statistics, including nanomedicine drug delivery industry global market size, regional shares, competitors with a nanomedicine drug delivery market share, detailed nanomedicine drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the nanomedicine drug delivery industry. This nanomedicine drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nanomedicine drug delivery involves using nanoscale materials and technologies to carry therapeutic agents directly to specific areas within the body. It increases the precision and control of treatment, ensuring optimal interaction with disease sites. Nanomedicine drug delivery enhances drug stability, absorption, and bioavailability, resulting in more effective outcomes. Its main advantage is reducing systemic exposure while maximizing therapeutic effectiveness.

The main product types of nanomedicine drug delivery include nanoparticles, liposomes, micelles, dendrimers, nanotubes, and others. Nanoparticles in nanomedicine drug delivery are nanoscale carriers engineered to deliver therapeutic agents directly to specific cells or tissues, enhancing drug effectiveness while reducing side effects. They are administered through various routes, such as oral, injectable, topical, and others, for multiple applications including oncology, cardiovascular diseases, neurology, infectious diseases, and others, and are used by a range of end-users, including hospitals, clinics, research institutes, and others.

The nanomedicine drug delivery market consists of revenues earned by entities by providing services such as drug formulation services, nanocarrier design services, clinical trial management services, regulatory consulting services, contract research services, and contract manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nanomedicine drug delivery market also includes sales of nanocarrier-based drug formulations, targeted drug delivery systems, sustained release nanomedicines, polymeric nanoparticles, lipid-based nanocarriers, and nanoemulsions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.